41 completed, 10 unknown, 7 terminated, 4 not yet recruiting. 69 Phase 2, 7 Phase 1, 4 Phase 3.
Follow Uterine Cervical Dysplasia: new trials by email Literature Review of Uterine Cervical Dysplasia trials Research Report on Uterine Cervical Dysplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of the Efficacy of HAL-PDT in CIN 3 Hexaminolevulinate (HAL) - Cervical Intraepithelial Neoplasia Grade 3 | Phase 2 | Not yet recruiting | Tongji Hospital | 260 | 2026-11-01 | 2026-10-23 |
| Adjuvant 5-Fluorouracil Following Thermal Ablation to Improve HPV Treatment Outcomes in Women With HIV in Kenya 5% 5-fluorouracil Topical Cream, Placebo Cream - HIV Infections, HPV Infection | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 140 | 2026-09-01 | 2026-08-27 |
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL) Loop Electrosurgical Excision Procedure (LEEP) or Cold Knife Conization (CKC), HAL 5% with illumination - Cervical Intraepithelial Neoplasia, Papillomavirus Infections | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 230 | 2026-07-01 | 2026-07-09 |
| Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities EGCG and Quinine Sulfate Vaginal Suppository, Placebo - High-risk HPV (Any Strain), LSIL, Low Grade Squamous Intraepithelial Lesion | Phase 2 | Recruiting | Amplexd Therapeutics, Inc. | 45 | 2026-04-30 | 2026-05-14 |
| PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia PVX4 Combination Product, Placebo Control - Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16 | Phase 2 | Recruiting | PapiVax Biotech, Inc. | 138 | 2026-04-01 | 2026-05-06 |
| Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV Nonavalent HPV vaccine (9vHPV) - HPV, High-risk HPV (Any Strain) | Phase 2 | Not yet recruiting | Institut d'Investigació Biomèdica de Bellvitge | 80 | 2026-02-01 | 2026-02-11 |
| Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya Artesunate vaginal inserts, Placebo vaginal inserts - Human Immunodeficiency Virus, Human Papillomavirus | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 120 | 2025-01-22 | 2026-05-14 |
| Efficacy of Topical 85% TCA in the Treatment of LSIL After Low-grade Abnormality of Screening Test: a Randomized Controlled Trial 85%TCA topical application, 3% acetic acid - Cervical Intraepithelial Neoplasia, Trichloroacetic Acid | Phase 2 | Unknown | Department of Medical Services Ministry of Public Health of Thailand | 44 | 2024-08-01 | 2024-11-14 |
| A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants With Cervical Intraepithelial Neoplasia ABI-2280 Vaginal Tablet/Insert - Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Terminated | Antiva Biosciences | 44 | 2022-09-10 | 2026-02-19 |
| A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation - Cervical Intraepithelial Neoplasia | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1080 | 2022-08-22 | 2025-02-03 |
| Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia Pembrolizumab - Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2021-06-30 | 2026-10-06 |
| Vvax001 Cancer Vaccine in Premalignant Cervical Lesions - Phase II Vvax001 therapeutic cancer vaccine - CIN3, Cervical Intraepithelial Neoplasia | Phase 2 | Unknown | University Medical Center Groningen | 18 | 2021-03-23 | 2023-08-29 |
| Immunohistochemical Staining of p16 for the Screening of Cervical Cancer p16 protein expression - Cervical Cancer Screening, p16 Protein | Phase 2 | Unknown | Lei Li | 250 | 2020-11-26 | 2020-12-03 |
| Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) Artesunate vaginal insert, Placebo vaginal insert - CIN 2/3, HPV Infection | Phase 2 | Recruiting | Frantz Viral Therapeutics, LLC | 78 | 2020-09-09 | 2025-10-02 |
| Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL PVX-2, Placebo - ASC-US, ASC-H | Phase 2 | Terminated | PapiVax Biotech, Inc. | 16 | 2019-05-22 | 2024-06-17 |
| Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions Glizigen® + Ocoxin-Viusid® - Carcinoma, Neoplasia; Intraepithelial, Cervix | Phase 2 | Unknown | Catalysis SL | 62 | 2019-03-11 | 2024-02-07 |
| A Efficacy and Safety Study of Composite Gel Containing Black Raspberry Extract in Removing HPV From Patients With Cervical Intraepithelial Neoplasia(CIN) After Cervical Conization Composite Gel Containing Black Raspberry, placebo - Cervical Intraepithelial Neoplasia, HPV | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 78 | 2018-12-01 | 2018-11-19 |
| A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia Nelfinavir - Cervical Dysplasia | Phase 2 | Withdrawn | The University of Texas Health Science Center, Houston | 2018-11-07 | 2020-11-12 | |
| Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer Nimotuzumab, Cisplatin, external-beam radiation - Neoplasms, Cervical Adenosquamous Cell Carcinoma | Phase 2 | Unknown | Zhujiang Hospital | 100 | 2018-03-20 | 2018-08-13 |
| IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3 Cyclophosphamide, Indomethacin, IRX-2 - Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion | Phase 2 | Terminated | University of Southern California | 10 | 2017-11-08 | 2025-04-13 |
Showing 20 of 69. Sign in to see all of them.
Uterine Cervical Neoplasms (18) · Papillomavirus Infections (16) · Squamous Intraepithelial Lesions (12) · Atypical Squamous Cells of the Cervix (8) · Precancerous Conditions (8) · Infections (3) · Neoplasms (3) · Acquired Immunodeficiency Syndrome (1) · Candidiasis, Vulvovaginal (1) · Carcinoma (1) · Carcinoma in Situ (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · HIV Infections (1)
Female Urogenital Diseases (69) · Female Urogenital Diseases and Pregnancy Complications (69) · Genital Diseases (69) · Urogenital Diseases (69) · Uterine Cervical Diseases (69) · Genital Diseases, Female (68) · Uterine Diseases (68) · Neoplasms (66) · Precancerous Conditions (61) · Pathological Conditions, Signs and Symptoms (27) · Neoplasms by Site (21) · Urogenital Neoplasms (20) · Genital Neoplasms, Female (19) · Uterine Neoplasms (18) · Communicable Diseases (17)
Imiquimod (4) · 5-aminolevulinic acid hexyl ester (3) · 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (2) · Celecoxib (2) · Cyclophosphamide (2) · GX-188 vaccine (2) · Indomethacin (2) · Lighting (2) · Papillomavirus Vaccines (2) · 5-aminolaevulinic acid-n-pentylester (1) · Acetaminophen (1) · Acetic Acid (1) · Adjuvants, Pharmaceutic (1) · Antigens (1) · Atropine (1)
National Cancer Institute (NCI) (3) · Photocure (3) · Barretos Cancer Hospital (2) · BioLeaders Corporation (2) · Genexine, Inc. (2) · GlaxoSmithKline (2) · Medical University of Vienna (2) · PapiVax Biotech, Inc. (2) · Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (2) · Takeda (2) · Tigris Pharmaceuticals (2) · UNC Lineberger Comprehensive Cancer Center (2) · AIDS Malignancy Consortium (1) · Advaxis, Inc. (1) · Albert Einstein College of Medicine (1)
United States (34) · China (8) · Canada (5) · South Korea (5) · France (4) · Germany (4) · Belgium (3) · Estonia (3) · Norway (3) · Puerto Rico (3) · Australia (2) · Austria (2) · Brazil (2) · Kenya (2) · South Africa (2)
Beihua Kong, MD (2) · Chemtai Mungo, MD, MPH (2) · Chi-Heum Cho, MD, PhD (2) · Cynthia J Goldberg, MD (2) · Jae-Kwan Lee, MD, PhD (2) · Jong Sup Park, MD, PhD (2) · Keith A Aqua, MD (2) · Mark H Einstein, MD (2) · Michele Follen, MD, PhD (2) · Peter Hillemanns, MD, PhD (2) · Ricardo D Reis, MD (2) · Robert Pfeffer, MD (2) · Tae Jin Kim, MD, PhD (2) · Youzhong Zhang, MD (2)
PMID 17586030, PMID 19118066, PMID 20812850, PMID 21907959, PMID 22914404, PMID 25467012, PMID 25937157, PMID 26100924, PMID 26386540, PMID 28285845, PMID 29304768, PMID 31220105, PMID 31576684, PMID 32975556, PMID 33175656, PMID 33558725, PMID 34907980, PMID 36607735, PMID 38330377, PMID 40313865, PMID 40907021
2008 (2), P01CA082710 (1), P30CA006973 (1), P30CA014089 (1), P30CA016672 (1), R21CA105696 (1), R34CA284983 (1), R37CA306827 (1), U01CA121947 (1), U10CA027469 (1), U10CA037429 (1), U10CA101165 (1)